Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Total Current Liabilities (2020 - 2026)

Edgewise Therapeutics has reported Total Current Liabilities over the past 7 years, most recently at $22.5 million for Q1 2026.

  • Quarterly results put Total Current Liabilities at $22.5 million for Q1 2026, up 6.76% from a year ago — trailing twelve months through Mar 2026 was $22.5 million (up 6.76% YoY), and the annual figure for FY2025 was $27.4 million, up 14.71%.
  • Total Current Liabilities reached $22.5 million in Q1 2026 per EWTX's latest filing, down from $27.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $27.4 million in Q4 2025 and bottomed at $9.2 million in Q2 2022.
  • Median Total Current Liabilities over the past 5 years was $16.8 million (2023), compared with a mean of $17.5 million.
  • The largest annual shift saw Total Current Liabilities surged 106.23% in 2022 before it rose 1.12% in 2023.
  • Over 5 years, Total Current Liabilities stood at $16.6 million in 2022, then grew by 1.12% to $16.8 million in 2023, then soared by 42.27% to $23.9 million in 2024, then rose by 14.71% to $27.4 million in 2025, then dropped by 17.64% to $22.5 million in 2026.
  • Business Quant data shows Total Current Liabilities for EWTX at $22.5 million in Q1 2026, $27.4 million in Q4 2025, and $21.6 million in Q3 2025.